tbuckley/cabot-search huggingface dataset:
Hepatic regeneration is associated with preservation of microsomal glucuronidation
Authors: W Zakko
Journal: Hepatology (1996)

Significant controversy exists regarding the regulation of glucuronidation during the process of hepatic regeneration. We used a partial hepatectomy rat model to elucidate the effects of hepatic regeneration on the various components of the microsomal glucuronidation system. Hepatic microsomes were prepared by standard sucrose density centrifugation, coupled with a modified technique involving Percoll centrifugation. Microsomal uridine diphosphate (UDP)-glucuronosyltransferase (UGT) protein expression and UGT messenger RNA (mRNA) levels were measured by Western and Northern blotting. UGT enzyme activity was determined toward two prototypical aglycones, p-nitrophenol and estrone, in intact and digitonin-treated microsomes. Microsomal uptake of the cosubstrate for all glucuronidation reactions, UDP-glucuronic acid (UDP-GlcUA), was determined using a rapid-filtration assay. Microsomal enrichment after hepatectomy was preserved only when the Percoll method was used. Microsomal UGT protein expression and UGT mRNA levels were unaltered after hepatectomy. UGT enzyme activity toward estrone was unchanged 1 day posthepatectomy compared with sham laparotomy controls. Similarly, p-nitrophenol glucuronide formation was unaffected by hepatic regeneration 1, 2, and 5 days posthepatectomy when digitonin-treated microsomes were used. Glucuronidation of p-nitrophenol in intact microsomes was increased in partial hepatectomy compared with sham-operated controls at 1 and 2 days. This increase was not attributable to changes in microsomal UDP-GlcUA uptake, which was comparable in both groups. We conclude that microsomal glucuronidation, in contrast to other well characterized hepatic metabolic functions, is highly preserved during liver regeneration.
Snakebite
Authors: W. E. Lockhart
Journal: JAMA (1966)

<h3>To the Editor:—</h3> Russell et al are recognized authorities on snakebite who are prejudiced against cryotherapy, which they have not used. Dr. Frederick A. Shannon met tragic death recently from rattlesnake bite, and their 112 cases without a death are now grimly 113, and one death. The statement, "we are inclined to agree with McCollough and Gennaro that cryotherapy is 'valueless' and that 'the combination in some instances of refrigeration and venom would seem to have contributed more to the necessity of amputation than with venom alone,'" reveals their bias and does not stand up to scientific criticism. The article quoted indicates that cryotherapy as set forth in my article (FRESHwater ice packed directly against the skin extending a foot above the bite applied early before swelling has obstructed circulation and maintained for six days continuously while the patient's body is kept warm with an electric blanket) was not used.
Neural Responses to Happy Facial Expressions in Major Depression Following Antidepressant Treatment
Authors: Cynthia Fu
Journal: American Journal of Psychiatry (2007)

Objective: Processing affective facial expressions is an important component of interpersonal relationships. However, depressed patients show impairments in this system. The present study investigated the neural correlates of implicit processing of happy facial expressions in depression and identified regions affected by antidepressant therapy. Method: Two groups of subjects participated in a prospective study with functional magnetic resonance imaging (fMRI). The patients were 19 medication-free subjects (mean age, 43.2 years) with major depression, acute depressive episode, unipolar subtype. The comparison group contained 19 matched healthy volunteers (mean age, 42.8 years). Both groups underwent fMRI scans at baseline (week 0) and at 8 weeks. Following the baseline scan, the patients received treatment with fluoxetine, 20 mg daily. The fMRI task was implicit affect recognition with standard facial stimuli morphed to display varying intensities of happiness. The fMRI data were analyzed to estimate the average activation (overall capacity) and differential response to variable intensity (dynamic range) in brain systems involved in processing facial affect. Results: An attenuated dynamic range of response in limbic-subcortical and extrastriate visual regions was evident in the depressed patients, relative to the comparison subjects. The attenuated extrastriate cortical activation at baseline was increased following antidepressant treatment, and symptomatic improvement was associated with greater overall capacity in the hippocampal and extrastriate regions. Conclusions: Impairments in the neural processing of happy facial expressions in depression were evident in the core regions of affective facial processing, which were reversed following treatment. These data complement the neural effects observed with negative affective stimuli.
Study to evaluate manipulation therapy
Authors: P. Gunby
Journal: JAMA (1983)

This summer marks the start of what could be the largest scientific effort yet to prove or disprove the usefulness of manipulation for treating back pain. The technique predates Hippocrates but to this day remains entangled in confusion and controversy. About 30 medical and osteopathic physicians and others researching manipulation will meet in Berne, Switzerland, Sept 11-17. Their goal: consensus on technique, on signs or symptoms that may call for or contraindicate manipulation, and even on terminology. The very word "manipulation," for example, does not have the same meaning for each of its practitioners. The American Association of Colleges of Osteopathic Medicine's latest<i>Glossary of Osteopathic Terminology</i>(Educational Council on Osteopathic Principles, 23 June 1982) lists 19 definitions under this heading. An abbreviated and general definition of manipulation might state that it involves various manual techniques of passive (the patient not actively participating) or active (patient moving in one direction
TESTING FOR TERATOGENICITY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAPAN
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obesity in adult survivors of childhood acute lymphoblastic leukemia: A follow-up report from the Childhood Cancer Survivor Study
Authors: E. G. Garmey, Q. Liu, C. A. Sklar, L. R. Meacham, M. Stovall, Y. Yasui, L. L. Robison, K. C. Oeffinger
Journal: Journal of Clinical Oncology (2007)

9518 Background: We previously reported an association between ≥ 20 Gy cranial radiotherapy (CRT) and obesity in adult survivors of childhood ALL. This follow-up study aimed to determine if, with time, (1) the prevalence of obesity and (2) the rate of BMI change were increased in ALL survivors in comparison with sibling controls. Methods: A longitudinal cohort comparing 1,451 adult survivors of childhood ALL (mean age 32.3 years) to 2,167 siblings of childhood cancer survivors (mean age 35.9 years). BMI was calculated from self- reported heights and weights and used to determine the prevalence of being overweight (25.0 ≤ BMI &lt; 30.0) or obese (BMI ≥ 30.0). Polytomous logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for being overweight or obese among ALL survivors compared to sibling controls. BMIs at baseline and follow-up (with a mean interval of 7.8 years) were used to calculate mean BMI increases per year occurring between these timepoints. Results: Age- and race-adjusted ORs for obesity among survivors compared with siblings are shown in the table . Notably, 10–19 Gy CRT was associated with an increased likelihood of being obese in comparison with siblings. In longitudinal analysis, survivors who were treated with CRT had a significantly greater net increase in BMI/year in comparison with siblings. At follow-up, 69.7% of females treated with ≥ 20 Gy CRT prior to the age of 10 were overweight (31.1%) or obese (38.6%). Conclusion: Cranial radiotherapy ≥ 10 Gy employed in the treatment of childhood ALL is strongly associated among both male and female survivors with increases in the prevalence of obesity and average BMI gains over time. Female survivors who received CRT ≥ 20 Gy, particularly those treated at a younger age, were most affected. [Table: see text] No significant financial relationships to disclose.
Commentaire de travail de L. Camellini et al., pp. 709
Journal: Endoscopy (2011)

See also: A randomized clinical trial comparing 22G and 25G needles in endoscopic ultrasound-guided fine-needle aspiration of solid lesionsEndoscopy 2011; 43(08): 709-715DOI: 10.1055/s-0030-1256482
Mechanisms of Kidney Cell Injury from Metals
Authors: Bruce A. Fowler
Journal: Environmental Health Perspectives (1993)

The most environmentally abundant toxic metals/metalloids (arsenic, cadmium, lead, and mercury) are each known to produce cell injury in the kidney but the molecular mechanisms underlying these events are now being elucidated. It is clear that the nephrotoxicity of these agents is due, in part, to the fact that urinary elimination is a major route of excretion from the body. The role(s) of molecular factors such as metal-binding proteins, inclusion bodies, and cell-specific receptorlike proteins that appear to influence renal tubule cell expression, have attracted increased interest as determinants that modulate cell populations as special risk for toxicity and renal cancer. The future of mechanistic toxicology studies with regard to how and why only certain renal cell populations become targets for toxicity from these metals/metalloids and other less common inorganic nephrotoxicants must focus on the molecular handling of these agents by target cell populations.
THE SHIP SURGEON.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Atypical mycobacteria in bone marrow histiocytes
Authors: R. A. Savage
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National survey among people who use drugs (PWUD) on opioid substitution treatment (OST) on their knowledge of hepatitis C virus (HCV) infection and barriers for treatment in Bulgaria
Authors: Marieta Simonova, Alexander Kantchelov, Georgi Vasilev, Borislava Peeva, Lyuba Hadzhiyska, Malin Stoyanov, Daniela Alexieva, Boryana Ekova, Emil Grashnov, Alexander Angelov, Marian Silyanovski, Georgi Koev, Tinka Nacheva, Mira Altankova, Temenujka Mateva Dechkova-Novakova, Faniq Taneva, Dora Atanasova, Velislava Martinova, Margarita Novoselska, Boyanka Kitova, Dimitar Vasilev, Dian Hursafov, Jechka Parusheva, Antoaneta Kumbieva, Adriana Solakova, Rumen Dimitrov, Cvetana Stoykova, Maria Dobreva, Lidia Gencheva, Ana Tomanova, Todor Kondurdzhiev, Slava Pavlova, Tanya Hadzhiolova, Lyudmila Mateva, Krum Katzarov
Journal: Journal of Hepatology (2020)
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Authors: Burkert Pieske, Carsten Tschöpe, Rudolf A. de Boer, Alan G. Fraser, Stefan D. Anker, Erwan Donal, Frank Edelmann, Michael Fu, Marco Guazzi, Carolyn S.P. Lam, Patrizio Lancellotti, Vojtech Melenovsky, Daniel A. Morris, Eike Nagel, Elisabeth Pieske-Kraigher, Piotr Ponikowski, Scott D. Solomon, Ramachandran S. Vasan, Frans H. Rutten, Adriaan A. Voors, Frank Ruschitzka, Walter J. Paulus, Petar Seferovic, Gerasimos Filippatos
Journal: European Journal of Heart Failure (2020)
Troxacitabine, an <scp>l</scp>-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies
Authors: Johann S. de Bono, Joseph Stephenson, Sharyn D. Baker, Manuel Hidalgo, Amita Patnaik, Lisa A. Hammond, Geoffrey Weiss, Andrew Goetz, Lillian Siu, Cecelia Simmons, Jacques Jolivet, Eric K. Rowinsky
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To assess the feasibility of administering troxacitabine, a unique l-nucleoside that is not a substrate for deoxycytidine deaminase–mediated catabolism, as a 30-minute intravenous (IV) infusion daily for 5 days. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated with escalating doses of troxacitabine as a 30-minute IV infusion daily for 5 days. Plasma and urine sampling was performed to characterize the pharmacokinetics and pharmacodynamics of troxacitabine. RESULTS: Thirty-nine patients received 124 courses of troxacitabine at eight dose levels ranging from 0.12 to 1.8 mg/m 2 /d. Severe neutropenia that was protracted (&gt; 5 days) and/or associated with fever, and skin rashes were consistently experienced by heavily (HP) and minimally pretreated (MP) patients at doses exceeding 1.2 and 1.5 mg/m 2 /d, respectively. At troxacitabine doses ≥ 1.2 mg/m 2 /d, treatment was often delayed 1 additional week for complete resolution of hematologic effects, resulting in lengthening of the treatment interval from every 3 to 4 weeks. Skin rash, palmar-plantar erythrodysesthesia, and thrombocytopenia were also observed and were occasionally severe, particularly at the highest doses. A patient with metastatic ocular melanoma experienced a partial response. Pharmacokinetics of troxacitabine were dose-independent; mean (SD) values for the volume of distribution at steady-state and clearance (Cl s ) were 60 (32) L and 161 (33) mL/min, respectively, on day 1. After treatment on the fifth day, terminal half-life values averaged 39 (63) hours, and Cl s was reduced by approximately 20%, averaging 127 (27) mL/min. The principal mode of drug elimination was renal. CONCLUSION: Recommended doses for phase II studies of troxacitabine as a 30-minute infusion daily for 5 days every 4 weeks are 1.5 and 1.2 mg/m 2 /d for MP and HP patients, respectively. Broad disease-directed evaluations of troxacitabine on this schedule and possibly less frequent schedules are warranted.
Kystoskopische Technik. Ein Lehrbuch der Kystoskopie, des Ureteren-Katheterismus, der Funktionellen Nieren-Diagnostik, Pyelographie, Intravesikalen Operationen.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PARIS
Journal: JAMA (1928)

<h3>The Abuse of Antisyphilitic Treatment in Heart Disease</h3> A discussion held before the Société médicale des hôpitaux de Paris has cleared up the indications for antisyphilitic treatment in subjects affected with cardiovascular disease. Because of the predilection of syphilis for these organs, and because the serologic reactions in old cases of syphilis are often uncertain, many practitioners prescribe antisyphilitic treatment to nearly all heart patients. Dr. Donzelot protested against this. In a general way, the specialists present were agreed that, even when the syphilitic nature of the cardiac lesions is evident, antisyphilitic treatment is far from meeting all the exigencies of the situation; that it must be used prudently, and that often it must be deferred until the state of functioning has been improved by other methods. <h3>May an Undue Allowance of Bread Exert Harmful Effects?</h3> The French are commonly regarded as the biggest bread eaters in the world. Several
Balanoposthitis
Authors: Richard D. Baughman
Journal: JAMA (1973)

<h3>To the Editor.—</h3> The letter by Marshall et al concerning "Balanoposthitis Secondary to Tetracycline Therapy" (223:559, 1973) implies a fixed drug eruption of similar mechanism to that seen with phenolphthalein. The case reports and photograph are quite compatible with the balanitis caused by<i>Candida albicans</i>. Unless the authors have excluded that possibility with a potassium hydroxide preparation, their conclusion is untenable.